Eggshell membrane ameliorates hepatic fibrogenesis in human C3A cells and rats through changes in PPARγ-Endothelin 1 signaling

Huijuan Jia1, Wanping Aw2, Kenji Saito1, Manaka Hanate3, Yukio Hasebe4 & Hisanori Kato1,3

1Corporate Sponsored Research Program “Food for Life,” Organization for Interdisciplinary Research Projects, The University of Tokyo, Tokyo, Japan, 2Institute of Advanced Biosciences, Keio University, Yamagata, Japan, 3Department of Applied Biological Chemistry, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Tokyo, Japan, 4ALMADO Inc., Tokyo, Japan.

Our previous nutrigenomic findings indicate that eggshell membrane (ESM) may prevent liver fibrosis. Here we investigated the effects and mechanisms underlying ESM intervention against liver injury by using DNA microarray analysis and comparative proteomics. In vitro hydrolyzed ESM attenuated the TGFβ1-induced procollagen production of human hepatocyte C3A cells and inhibited the expression of Endothelin 1 (EDN1) and its two receptors, and extracellular matrix components. In vivo male Wistar rats were allocated into a normal control group, a CCl4 group (hypodermic injection of 50% CCl4 2×/wk) and an ESM group (20 g ESM/kg diet with CCl4 injection) for 7 wks. Dietary ESM ameliorated the elevated activity of ALT/AST, oxidative stress and collagen accumulation in liver, accompanied by the down-regulated expression of Edn1 signaling and notable profibrogenic genes and growth factors as well as peroxisome proliferator-activated receptor gamma (PPARγ). Concomitantly, the decreased expressions of Galectin-1 and Desmin protein in the ESM group indicated the deactivation of hepatic stellate cells (HSCs). Through a multifaceted integrated omics approach, we have demonstrated that ESM can exert an antifibrotic effect by suppressing oxidative stress and promoting collagen degradation by inhibiting HSCs’ transformation, potentially via a novel modulation of the PPARγ-Endothelin 1 interaction signaling pathway.

En eggshell membrane (ESM) is a natural material that can be easily obtained as clean, nontoxic and low-priced waste from the food industry1,2. Due to properties such as its high surface area, porous structure, inert nature, and water permeability, ESM has been used in metallurgy and bioremediation applications such as the recovery of gold from electroplating waste water3 and platforms for enzyme immobilization4. Notably, these studies did not deal with the food applications of ESM, although ESM contains high amounts of collagenized fibrous proteins.

Eggshell meal (both shell and membrane) has been officially recognized by the Association of American Feed Control Officials as a safe feed additive for both companion and livestock animals since 19825. The safety of ESM as a novel dietary supplement was confirmed by Ruff et al. in 20125. They also reported that ESM can suppress the production of tumor necrosis factor-alpha in cultures of peripheral blood mononuclear cells, revealing that ESM is a consumable anti-inflammatory product. As a clinical treatment, ESM was shown in human trials to maintain healthy joint and connective tissues, which may be the result of the combination of various components6. Notably, however, most ESM is still discarded to landfills together with eggshells, without any pretreatment7. In Japan, the annual generation of discarded ESM waste from food processors is estimated to be over 7,000 tons. The disposal of ESM and eggshells creates an environmental and financial burden, and alternative uses for these materials will thus be of great benefit.

In our previous work, dietary ESM treatment altered the expression of genes involved in rat liver extracellular matrix (ECM) homeostasis by down-regulating the expressions of collagen type I alpha 1 (Col1a1), integrin beta-like 1, decorin, asporin, and lumican7. Additionally, serum obtained from rats given the ESM diet suppressed the expression of COL1A1 and COL1A2 in human hepatocyte C3A cells8. On the basis of these nutrigenomic findings obtained in vivo and ex vivo, we hypothesize that ESM in the diet may help prevent liver fibrosis, which is the main cause of liver cirrhosis. We designed the present study to...
investigate the beneficial effects of hydrolyzed ESM (HEM) against transforming growth factor beta 1 (TGFβ1)-induced collagen production by C3A cells. To test this hepatoprotective role in vivo, we subsequently used a carbon tetrachloride (CCl₄)-induced liver injury model in rats, and the underlying mechanisms were elucidated by transcriptome profile characterization using a DNA microarray and quantitative proteomic platform using isobaric tags for relative and absolute quantification (iTRAQ) technology.

**Results**

**Cytotoxicity and procollagen production in TGFβ1-treated C3A cells.** After a 96-h TGFβ1 treatment, the LDH activities in the HEM0, HEM0.5 and HEM2 groups were 1.77 ± 0.03, 1.86 ± 0.12 and 1.66 ± 0.05, respectively, compared to CON at 1.00 ± 0.10. This showed no evidence of cell toxicity with either of the HEM concentrations. Procollagen Type I C-peptide production was significantly increased in the HEM0 group, and the effect was diminished by both 0.5 and 2 mg/mL of HEM supplementation (Fig. 1).

**Effects of HEM addition on cellular gene expression.** The results of the real-time RT-PCR indicated that HEM supplementation significantly down-regulated the expression of the genes for actin, alpha 1 (ACTA1), a vital marker of hepatic stellate cell (HSC) activation, and the following ECM components and profibrogenic factors: COL1A1; collagen, type III, alpha 1(COL3A1); spondin 1, ECM protein (SPON1); asporin (ASPN); tissue metallopeptidase inhibitor 1 (TIMP1), as well as the potent vasoconstrictor peptide Endothelin 1 (EDN1) and its type A (EDNRA) and type B (EDNRB) receptors. The genes encoding latent transforming growth factor beta binding protein 1 (LTBP1); and chemokine (C-C motif) ligand 2 (CCL2) were also significantly down-regulated (Fig. 1).

**Changes in body and organ weights.** Significant body weight changes between the CON and CCl₄ groups were observed starting from the 28th day, and this trend was maintained up to the last day with more significant differences. However, the ESM group showed a tendency for higher body weights compared to the CCl₄ group from the 21st day, suggesting that ESM prevented the body weight decrease in the rats (Fig. 2a). There were no significant differences in food intake or organ weights between the CCl₄ and ESM groups (Suppl. Table S2).

**Biochemical changes in liver function and lipid peroxidation contents.** The liver functions measured by plasma enzyme activities are shown in Table 1. An approximate fourfold increase in AST and fivefold increase in ALT activity could be observed after 7 wks of repeated CCl₄ injection compared to the CON rats. This marked liver damage was significantly attenuated by ESM treatment, following which the AST and ALT activities were decreased by 41% and 51%, respectively.

The CCl₄-administered rats had elevated plasma and liver TBARS levels, indicating marked oxidative stress induced by CCl₄. ESM treatment for 7 wks significantly normalized the plasma TBARS level compared to that of the CON group. This may be due to relatively lower lipid peroxidation in the liver. In addition, the plasma marker of liver fibrosis, ELF score, showed strong tendency (P = 0.07) of improved fibrotic state by dietary ESM (Table 1).

**Histopathology.** Since a high TBARS level can be attributed to membrane lipid peroxidation, which is one cause of hepatic injuries as a result of CCl₄-induced free radical production, we conducted a histological examination using H&E staining (Fig. 2c). In the CCl₄-injected rats, the liver structure of the hepatic parenchyma and blood and bile duct was disordered. Various histological changes

Figure 1 | Effects of HEM on procollagen Type I C-peptide production in media, and gene expression in TGFβ1-treated C3A cells. CON, C3A cells without TGFβ1 stimulation; HEM0, without HEM addition; HEM0.5 and HEM2, 0.5 and 2 mg/mL of HEM addition, respectively. Results are means ± SE in each group (n = 3). Data with different letters (a, b, c) are significantly different at P < 0.05 by Dunnett’s test.
to the liver such as ballooning degeneration and infiltration of inflammatory cells were observed in the CCl4 group compared to the CON group. In contrast, the sections of the livers from rats in the ESM group show ameliorated liver structure.

**Hepatic collagen content.** Fig. 2d depicts liver sections stained with Sirius red/Fast green, which is used to visualize collagen in a deep purplish red color. Our image analysis revealed that the CCl4 administration induced significant collagen deposition around pericentral areas which started to extend into the hepatic lobules to separate them. The ESM diet for 7 wks partially preserved the normal architecture of the parenchyma. Corroborating the histopathological analysis, the biochemical findings showed that the fibrosis index in the ESM group (22.5%, $P < 0.05$) revealed by

### Table 1 | Biochemical changes in rat hepatic function and oxidant status

|                | CON     | CCl4    | ESM     |
|----------------|---------|---------|---------|
| AST (Karmen)   | 56.12 ± 2.34a | 207.79 ± 25.0b | 111.68 ± 17.94c |
| ALT (Karmen)   | 8.09 ± 0.93a | 38.40 ± 7.81b | 18.98 ± 4.63a |
| Albumin (g/dL) | 4.70 ± 0.21  | 4.84 ± 0.21  | 4.45 ± 0.11  |
| Total protein (g/dL) | 6.95 ± 0.17 | 7.12 ± 0.37 | 6.69 ± 0.14 |
| TBARS (µM)     | 3.92 ± 0.29a | 5.11 ± 0.46b | 3.97 ± 0.31a |
| Liver TBARS (µmol/g liver) | 0.46 ± 0.02a | 0.74 ± 0.05b | 0.60 ± 0.03a |
| Hyaluronic acid (ng/ml) | 45.28 ± 6.96a | 77.11 ± 13.14b | 60.30 ± 13.21ab |
| Timp1 (ng/ml)  | 3.74 ± 0.23a | 5.76 ± 0.31b | 4.81 ± 0.32b |
| PIINP (ng/ml)  | 0.53 ± 0.10a | 0.91 ± 0.11b | 0.78 ± 0.10ab |
| ELF score      | 5.59 ± 0.20a | 6.69 ± 0.24b | 6.15 ± 0.24ab |

CON, control rats; CCl4, rats administered only CCl4; ESM, rats administered CCl4 and ESM (20 g kg⁻¹). Results are means ± SE in each group (n = 6). Data with different letters (a,b,c) are significantly different at $P < 0.05$ by Dunnett’s test.
collagen deposition was significantly lower than that in the CCl4 group (25.4%), and comparable to the 21.9% in the livers of the normal animals (Fig. 2b).

Variations in the hepatic gene expression profile. Three pairs of comparisons were performed to identify the hepatic gene expression associated with CCl4 administration and the ESM diet. Among the total analyzed genes, 444 genes showed a change of more than 1.5-fold as differentially expressed genes in response to the CCl4 administration (Fig. 3a). In the ESM-fed rats, 22 genes were up-regulated and 93 genes were down-regulated compared to the CCl4 rats. As some genes had no annotation in the database, 83 genes out of the 115 probes were counted as differentially expressed genes in the rat liver. Functional categorizing and clustering for changed genes by ESM were assigned according to the IPA, which revealed 'Hepatic Fibrosis/HSCs Activation' as the top canonical pathway. The three highest ranked functions are involved in 'Liver Necrosis/Cell Death,' 'Liver Cirrhosis,' and 'Liver Proliferation.' These results indicate that the ESM treatment had a notable effect on the CCl4-induced injury. The list of the changed genes is further detailed in Suppl. Table S4.

As similar to the HEM’s regulatory action in C3A cells, the ESM diet transcriptionally down-regulated the following multiple hepatic
fibrotic gene expressions, which are involved in cytokine signaling, collagen synthesis, HSCs activation, and ECM turnover: Colla1; collagen, type I, alpha 2(Colla1); Spoun1; Aspn; Spp1; Timp1; Edn1; Ednra; Ednrb; transforming growth factor beta 3 (Tgfβ3); Lifrb1; latent transforming growth factor beta binding protein 4 (Ltbpb4), platelet-derived growth factor receptor (Pdgfr), and vascular endothelial growth factor D (Vegfd), and the ESM diet up-regulated chymotrypsin-like elastase family, member 1 (Cela1), a degradation protease of ECM elastin, and peroxisome proliferator-activated receptor gamma (PPARγ) (Fig. 3b).

Comparative proteome analysis by iTRAQ. When we classified the proteins as significantly regulated or not, we included a 1.2-fold cut-off for the 1,044 unique proteins identified at more than the 95% confidence level. According to this criterion, we screened 219 proteins, out of which 71 proteins were up-regulated and 148 proteins were down-regulated in the ESM group compared to the CCl4 group. These proteins were classified into 10 hepatic functional categories, in which the confidence threshold was more than 1.25 using the IPA classification system (Fig. 4a). The top five molecular function categories were 'Liver Hyperplasia/Hyperproliferation,' 'Increased Levels of Albumin,' 'Liver Steatosis,' 'Liver Inflammation/Hepatitis,' and 'Liver Fibrosis,' which were complementary to that of the transcriptome.

As shown in Table 2, we selected nine differential proteins which were involved mainly in ECM accumulation and HSC activity. They were all significantly reduced after the ESM diet compared to the CCl4 group: Galectin-1 (Gal-1, Lgals1), which is generated by activated HSCs and participates in galactoside binding, thereby inducing different intracellular signaling pathways leading to the proliferation of HSCs19, desmin, an HSC activation-related protein; Sertorelin, which could induce a significant increase in procollagen I(I) mRNA expression20; Collagen alpha-1(I) chain (Col1a1); Collagen alpha-2(I) chain (Col1a2); GTP-binding nuclear protein Ran, which is involved in many aspects of nuclear function and the in vivo down-regulation of Ran protein resulting in enhanced apoptosis and reduced tumor growth12; Solute carrier family 2, facilitated glucose transporter member 1(Glut1, Slc2a1), a key rate-limiting factor for the transport and metabolism of glucose, whose expression is increased in hepatocellular cancer (HCC) and which promotes the tumorigenicity of HCC cells13,14; Aspartate aminotransferase, cytoplasmic; and Casein kinase II subunit beta, a polypeptide increased in liver15. The validation of some of these differential protein expressions is shown in Fig. 4b.

Western blotting analysis of hepatic p-PPARγ protein levels. Levels of hepatic p-PPARγ were significantly lower both in CCl4 and ESM groups compared to the CON group, whereas dietary ESM restored this decrease by approximately fourfold as to CCl4 group (Fig. 4c).

Discussion
Hepatic fibrosis is a dynamic process characterized by a central role of HSCs, which are activated from quiescent HSCs into a myofibroblast-like phenotype in response to hepatocyte injury, followed by the secretion and deposition of profibrogenic mediators and ECM components20. As such, the inhibition of HSC activation is regarded as one of the essential mechanisms to prevent fibrogenesis. In the present study, to investigate the bioavailability of ESM in the process of hepatic fibrosis, we utilized a stimulation model of TGFβ1 (which is known as a key regulator in HSC activity in vitro) by using soluble hydrolyzed products of ESM, and we used a CCl4-induced hepatic injury model in vivo that causes oxidative stress.

In the cellular investigation, we investigated how HEM blocked TGFβ1-induced fibrogenesis reflected by the markedly low levels of ECM components and the marker of HSC activation. With HEM supplementation, we observed significantly down-regulated expressions of a powerful vasoconstrictor peptide, EDN1, and its two receptors EDNRA and EDNRB. Under normal conditions, the sinusoidal endothelium is the major source of EDN1, which appears to be important in intrahepatic circulatory homeostasis. However, during stimulation by a number of exogenous factors such as TGFβ3, EDN1 synthesis shifts to not only induce stellate cell proliferation but also increases ECM production21 by virtue of the expression of EDNRA and EDNRB22. EDN1 exhibits an autocrine effect on HSCs and is involved in both HSC activation and the contractile response of HSCs to destroy the graft sinusoidal microcirculation balance23.

Importantly, a large body of experimental literature suggests that EDNRA and EDNRB expression correlates with the severity of the disease24, and therapy using an EDN receptor antagonist directed at intervening in the EDN1 signaling pathway had significant therapeutic potential in patients with liver disease25. Given the important role of EDN1 in fibrosis, our present findings at the cellular level suggest that HEM suppresses the EDN1 signaling network via the down-regulation of EDNRA and EDNRB expression, which in turn contributed to the cells’ increased resistance to exogenous TGFβ1-stimulated fibrosis.

We subsequently comprehensively investigated the beneficial functions of ESM in vivo. We found that dietary ESM also exhibited potential inhibitory effects on hepatic injury and fibrosis induced by CCl4 in rats, as evidenced by the rats’ decreased abdominal fat weights, improved plasma levels of ALT, AST, TBARS and hepatic TBARS, and the abnormal accumulation of collagen and degree of histological changes. Accordingly, we investigated the changes in hepatic gene and protein profiles related to relevant metabolic pathways to elucidate the underlying molecular mechanisms.

Consistent with the low collagen accumulation in the ESM group, significantly down-regulated ECM synthesis, degradation and turn-over-related genes suggest that ESM is related to both the ECM synthesis and the degradation pathway involved in fibrosis. Although there was no significant difference in the expression of Acta1, the down-regulated HSC activation-related markers such as Gal-1 transcript and protein, desmin protein, and the mRNA levels of alpha-crystallin B, Edn1 and its two receptors might contribute to the low proliferation and activation of HSCs and low ECM production.

HSC activation results in the secretion of several pro-fibrogenic cytokines, such as TGFβ1, platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF) and insulin-like growth factor (IGF)16,23. TGFβ1, TGFβ2 and TGFβ3 (which share approx. 70% sequence identity and exhibit distinct functions in vivo) are structurally homologous dimeric proteins and physiologically important in regulating multiple biological processes, including proliferation, ECM synthesis and immune response23,24. TGFβ1 is well known to stimulate HSC proliferation and the synthesis and secretion of ECM. However, in the present study’s ESM group, Tgfb3, not Tgfb1, was differentially down-regulated, the relevance of which is supported by our previous finding that the expression of Tgfb3 was 2.6-fold higher than the Tgfb1 expression in a CCl4-induced rat cirrhosis model for 19 wks2. It is worth noting that cells secrete TGFβs as a small latent complex (TGFβ–LAP–LTBP) composed of the mature dimeric TGFβs molecule and the two respective N-terminal pro-domains (LAP and LTBP). TGFβs remains inactive while being recruited within this complex; however, when the liver has been injured, several proteases (metalloproteases, elastase and plasmin) cleave LTBP from the complex, releasing TGFβ and LAP. In this process, LTBPs regulate the TGFβs activity by facilitating its secretion, localizing the latent TGFβs to specific sites in the ECM22. The down-regulation of Tgfb3, Ltbps and the other growth factor-related genes such as Pdgfr and Vegfd may be one of the crucial mechanisms of ESM protection against HSC activation and fibrogenesis.
We further investigated the upstream regulator of the activation of HSCs in detail. We observed a link between EDN1 and PPARγ, a nuclear transcription factor that modulates the expression of various genes involved in many biological processes. PPARγ expression significantly decreased after HSC activation, in which HSCs primarily lose the vitamin A lipid droplets and become myofibroblasts. The expression of PPARγ transforms HSCs back to a quiescent state, and the storage capacity of retinol palmitate fat is restored; thus the induction of PPARγ expression can significantly counteract the development of hepatic fibrosis. Notably, PPARγ activators are targeted as a novel therapeutic strategy to inhibit enhanced Edn1 signaling under several stresses, for example cardiac fibrosis.

Congruently with these reports, the significantly high levels of PPARγ mRNA expression and p-PPARγ protein, and restored expressions of Edn1, Ednra and Ednrb that we observed in the present ESM group suggest a modulatory role of ESM in PPARγ-Endothelin 1 signaling, HSC activation and the attenuated microcirculatory disturbance and graft function, and eventually the formation of fibrosis. This can also be supported by the down-regulation of the retinol-binding proteins (Rbps, 1.2-fold) and lecithin-retinol acyltransferases (Lrats, 0.8-fold). As this is a novel and interesting finding in our study, future experiments are needed to confirm this Edn1-PPARγ interaction by comparing ESM supplementation and Edn1 blockades combined with PPARγ activators to determine
whether similar cellular mechanisms or their synergic action are responsible for the improved liver function.

Collectively, our findings indicate that ESM attenuates the enhanced HSC activation through the PPARγ-mediated repression of the Edn1 signaling pathway, thereby down-regulating growth factors, ECM components, cytokines, chemotactic factors, oxidative stress and other factors (Suppl. Table S4 and Suppl. Figure 1) simultaneously, which interact with each other forming a complex network of remodeling regulation of hepatic fibrosis. These hypothetical relationships are schematically depicted in Fig. 5.

To our knowledge, we have provided the first instance of a multi-omics study of ESM, which is expected to be impactful since the present findings not only provide information about the functions and bioavailability of ESM but also contribute to the field of environmental protection, which is increasingly important. In addition, given the concerns about impediment of Edn1 receptor antagonists in clinical trials, we propose that ESM, which is a natural, nontoxic and low-priced food waste could be a candidate for the nutritional prevention and treatment of liver fibrosis in humans. This is the most intriguing and attractive implication of this study.

In conclusion, on the basis of the nutrigenomic and proteomics information obtained by our use of a DNA microarray and a quantitative proteomic platform, ESM is a safe and natural byproduct of egg processing which possesses potent protective biochemical functions against liver injury and fibrosis. The mechanism may be associated with its tissue repair effects on the suppression of oxidative stress, improving lipid (Suppl. materials) and ECM accumulation and hepatic function, and regulating genes and proteins related to drug metabolism, the activation of HSCs and fibrogenesis by a potential novel modulation of the PPARγ-Endothelin 1 interaction signaling pathway. Through the multifaceted integrated omics approach, we have indicated that ESM may be useful for maintaining human health, especially with regard to liver fibrosis and cirrhosis.

Methods

Culture of C3A cells. Human C3A hepatocyte cells (CRL-12461, ATCC, Manassas, VA, USA), which are facile in producing collagen under exogenous stimulations, were plated onto the inner wells of 6-well tissue culture plates at a density of 1.3 \times 10^5 cells per well and cultured in normal growth medium: DMEM (Sigma-Aldrich, St. Louis, MO) containing 2% fetal bovine serum and 1% penicillin/streptomycin for 24 h, then conditioned in serum-free medium with 10 mg/L transferrin (Sigma-Aldrich) and 10 mg/L insulin (Alpha Diagnostic, San Antonio, TX) for 72 h. The cells were then further conditioned in fresh serum-free medium with 500 \mu M sodium oleate (Sigma-Aldrich) for 24 h. Then, cells were conditioned in serum-free medium further supplemented with 0.5 mg/L TGFβ1 (Calbiochem-Merck, Nottingham, UK) and incubated for 96 h. The medium was changed every 24 h with fresh medium further supplemented with 0 (HEM0), 0.5 (HEM0.5) or 2 (HEM2) mg/mL HEM. Cells without TGFβ1 exposure were used as controls (CON). All cultures were kept at 37°C in a humidified atmosphere incubator with 5% CO₂. Harvested cells were stored at −20°C.

Cytotoxicity under all incubation conditions was assessed by lactate dehydrogenase (LDH) leakage into the culture medium using a LDH-Cytotoxic Test kit (Wako Pure Chemical Industries, Tokyo). Procollagen Type I C-peptide was determined using an enzyme immunoassay kit (TaKaRa Bio, Shiga, Japan). Protein concentrations were determined by Bradford assay.

Table 2 | Selected potential biomarker proteins differentially expressed between CCl4 and ECM groups by iTRAQ analysis Partial list of proteins

| Accession no. | Protein name  | Gene name  | CCl4 vs. CON (Fold change) | ESM vs. CCl4 (Fold change) |
|---------------|--------------|------------|---------------------------|---------------------------|
| P12346        | Serotransferrin | Tf         | 1.19                      | 0.81                      |
| P11762        | Galectin-1   | Lgals1     | 1.52                      | 0.72                      |
| P02454        | Collagen alpha-1(II) chain | Col1a1     | 1.17                      | 0.89                      |
| P02466        | Collagen alpha-2(II) chain | Col1a2     | 1.14                      | 0.94                      |
| P62828        | GTP-binding nuclear protein Ran | Ran         | 1.58                      | 0.81                      |
| P11167        | Solute carrier family 2, facilitated glucose transporter member 1 | Slc2a1     | 2.12                      | 0.61                      |
| P13221        | Aspartate aminotransferase, cytoplasmic | Got1       | 1.02                      | 0.83                      |
| P67874        | Casein kinase II subunit beta | Csnk2b     | 1.21                      | 0.67                      |
| P48675        | Desmin       | Des         | 1.58                      | 0.58                      |

CON, control rats; CCl4, rats administered CCl4; ESM, rats given CCl4 and ESM (20 g kg⁻¹).

Figure 5 | Schematic representation of the antifibrotic effects of ESM against carbon tetrachloride (CCl4)-induced liver injury in rats. Green and red arrows express the down- or up-regulation by dietary ESM, respectively.
Animals and experimental design. Three-week-old male Wistar rats (50–57 g) obtained from Charles River (Tokyo) were housed under controlled conditions (22 ± 1 °C, 50%–60% relative humidity and 12 h light–dark cycles) with free access to tap water and diet throughout the study period. One week after acclimatization with an American Institute of Nutrition-93G powdered diet, the rats were randomly allocated into three groups of six animals per group: the normal control group (CON), the positive drug group receiving CQI (CG1), and the group receiving CQI plus a 20 g/kg diet of EMS powder (ESM). Liver injury was induced in the latter two groups by a hypodermic injection of 50% CCl4 (in olive oil), 1 mL/kg of body weight 2 wk for 7 wks. Rats in the CON group were similarly injected with olive oil. The rats’ body weights were recorded 2 wk/wk to adjust the CCl4 dosage.

At the end of the 7-wk experimental period, after an overnight starvation (12 h), all of the rats were euthanized with sodium pentobarbital (1 mg/kg body weight i.p.). Blood samples were obtained from the carotid artery and centrifuged immediately at 800 × g for 15 min at 4 °C. The collected plasma was kept at −80 °C until the assays. Liver, kidney, spleen, adipose tissues and testes were excised and weighed. All of the tissues were frozen with liquid nitrogen and preserved at −80 °C. All rats received humane care in accord with the guidelines of the Animal Usage Committee of the University of Tokyo, which gave prior approval to this study (Approval No. P13-768).

Biochemical analysis in rats. We measured the concentrations of alanine aminotransferase (ALT), aspartate aminotransferase (AST), albumin and total protein in plasma as markers of hepatic function by using the respective antibody kits (Wako, Tokyo). Lipid peroxidation parameters in the plasma and the liver, i.e., TBARS (thiobarbituric acid reactive substances) were determined spectrophotometrically with the NWSLSTM Malondialdehyde Assay Kit (NWK-MDA-TBARS, Northwest Life Science Specialties, Vancouver, WA). Concentrations of plasma TIMP1, amino-terminal propeptide of type III procollagen (PIIINP) and hyaluronic acid were measured by using the ELISA (R&D Systems Inc., Minneapolis, MN, USA; Cloud-Clone Corp., Houston, TX, USA; and Biotech Trading Partners, Encinitas, CA, USA; respectively), according to manufacturer’s instructions. The enhanced liver fibrosis (ELF) score was calculated using the following equation: ELF score = 2.494 + 0.846 ln (Hyaluronic acid) + 0.735 ln (PIIINP) + 0.391 ln (TIMP1)³⁴.

Liver histological assay. A portion of the left lobes of the livers was embedded in Optimal Cutting Temperature compound (Sakura Finetek, Torrance, CA), then snap-frozen in liquid nitrogen. Five-micrometer-thick sections were stained with Sirius red/Fast green staining (Cosmo Bio, Tokyo; detailed in the Supplementary text). Collagen measurement in liver sections. Collagen quantification was performed by Sirius red/Fast green staining (Cosmo Bio, Tokyo; detailed in the Supplementary Methods text).

Total RNA extraction and real-time RT-PCR. We extracted the total RNA from harvested cells and frozen rat liver by using TRIzol reagent and the RNA isolation Kit³⁵, respectively. The primers for the real-time RT-PCR analysis were designed using a web application (PRIMER3), and their sequences are given in Suppl. Table S1. The expression values for each specific gene were normalized against the GAPDH or 18S rRNA expression levels in the cell or animal samples, respectively, and they are shown as the fold-change value of normalized mRNA amounts compared to those of the CON group.

Hepatic cDNA microarray analysis and ingenuity® pathway analysis. We conducted a hepatic cDNA microarray analysis as described previously³⁶. Affymetrix GeneChip Rat Genome 230 2.0 Arrays (Affymetrix, Santa Clara, CA) were used for the genome-wide expression profiling. We analyzed the scanned images with the Genome-Wide Expression Suite (WES) software (Affymetrix, Santa Clara, CA, USA) and calculated the expression levels of each gene as the normalized difference value (NDEV) according to the manufacturer’s instructions. The data were analyzed with a one-way analysis of variance (ANOVA), and the Dunnett’s test was used to evaluate the significant differences of the means at the level of P < 0.05.

Statistical analysis. The results of the cell culture and animal experiments are reported as means ± SE of three wells or six rats, respectively. The data were analyzed with one-way ANOVA using the Tukey–Kramer test. In all cases, P < 0.05 was considered to be statistically significant.

References

1. Jia, H. et al. Transcriptional profiling in rats and an ex vivo analysis implicate novel beneficial function of egg shell membrane in liver fibrosis. J Funct Foods 5, 1611–1619 (2013).

2. Jia, H., Takahashi, S., Saito, K. & Kato, H. DNA microarray analysis identified molecular pathways mediating the effects of supplementation of branched chain amino acids on CCl4-induced cirrhosis in rats. Mol Nutr Food Res 57, 291–306 (2013).

3. Ishikawa, S.-I., Suyama, K., Arihara, K. & Itoh, M. Uptake and recovery of gold ions from electroplating wastes using eggshell membrane. Bioresour Technol 81, 201–206 (2002).

4. Ohto-Fujita, E. et al. Hydrolyzed eggshell membrane immobilized on phosphorylcholine polymer supplies extracellular matrix environment for human dermal fibroblasts. Cell Tissue Res 345, 177–190 (2011).

5. Ruff, K., J. Endres, J. R., Clevell, A. E., Szabo, J. R. & Schauss, A. G. Safety evaluation of a natural eggshell membrane-derived product. Food Chem Toxicol 50, 604–611 (2012).

6. Ruff, K. J., DeVore, D. P., Leu, M. D. & Robinson, M. A. Eggshell membrane: a possible new therapeutic for joint and connective tissue disorders. Results from two open-label human clinical studies. Clin Interv Aging 4, 235–240 (2009).

7. Tsai, W. T. et al. Characterization and adsorption properties of eggshells and eggshell membrane. Bioresour Technol 97, 488–493 (2006).

8. Pellicoro, A. et al. Elastin accumulation is regulated at the level of degradation by macrophage metalloelastase (MMP-12) during experimental liver fibrosis. Hepatology 55, 1965–1975 (2012).

9. Expelt, M. V. et al. Novel roles of galectin-1 in hepatocellular carcinoma cell adhesion, polarization, and in vivo tumor growth. Hepatology 53, 2097–2106 (2011).

10. Maeda, N. Stimulation of Proliferation of Rat Hepatic Stellate Cells by Galectin-1 and Galectin-3 through Different Intracellular Signaling Pathways. J Biol Chem 278, 18938–18944 (2003).

11. Brüde, K. R., Crawford, D. H. G. & Ramm, G. A. Identification and Characterization of the Hepatocellular Cell Transferrin Receptor. J Am Pathol 162, 1661–1667 (2003).

12. Tietze, N. et al. Induction of Apoptosis in Murine Neuroblastoma by Systemic Delivery of Transferin-Shielded siRNA Polyplexes for Downregulation of Ran. Oligonucleotides 18, 161–174 (2008).

13. Amann, T., Kirovski, G., Boursas, A. K. & Hellerbrand, C. Analysis of a promoter polymorphism of the GLUT1 gene in patients with hepatocellular carcinoma. Mol Membr Biol 28, 182–186 (2011).

14. Kitamura, K. et al. Proliferative activity in hepatocellular carcinoma is closely correlated with glucose metabolism but not angiogenesis. J Hepatol 55, 846–857 (2011).

15. Wang, F. et al. Gene expression studies of hepatitis virus-induced woodchuck hepatocellular carcinoma in correlation with human results. Int J Oncol 30, 33–44 (2007).

16. Sebastiani, G. et al. Accelerated CCl4-Induced Liver Fibrosis in Hpy−/− Mice, Associated with an Oxidative Burst and Precocious Profibrogenic Gene Expression. PloS one 6, e25138 (2011).

17. Zhan, S. & Rockey, D. C. Tumor necrosis factor alpha stimulates endothelin-1 synthesis in rat hepatostellate cells in hepatic wound healing through a novel IKK/INK pathway. Exp Cell Res 317, 1040–1048 (2011).

18. Rockey, D. C. Hepatic fibrosis, stellate cells, and portal hypertension. Clin Liver Dis 10, 459–479, vi–vii (2006).

19. Li, T., Shi, Z. & Rockey, D. C. Preproendothelin-1 expression is negatively regulated by IFNγamma during hepatic stellate cell activation. Am J Physiol Gastrointest Liver Physiol 302, G948–957 (2012).

20. He, C., Miao, X., Li, J. & Qiu, H. Angiotensin II induces endothelin-1 expression in human hepatic stellate cells. Dig Dis Sci 58, 2542–2549 (2013).

21. Principe, A. et al. The hepatic apelin system as a new therapeutic target for liver disease. Hepatology 48, 1193–1201 (2008).

22. Khimji, A. K. & Rockey, D. C. Endothelin and hepatic wound healing. Pharmacol Rev 63, 512–518 (2011).

23. Qiang, H. et al. Differential expression genes analyzed by cDNA array in the regulation of rat hepatic fibrogenesis. Liver Int 26, 1126–1137 (2006).

24. Zhang, Y. et al. Hydroxyasfofol yellow A protects against chronic carbon tetrachloride-induced liver fibrosis. Eur J Pharmacol 660, 438–444 (2011).

25. Huang, S. S. Cellular growth inhibition by IGBP3-1 and TGF-1 requires LRP-1. FASEB J 17, 2068–2081 (2003).
26. Mezaki, Y. et al. Elevated expression of transforming growth factor β3 in carbon tetrachloride-treated rat liver and involvement of retinoid signaling. *Int J Mol Med* 29, 18–24 (2011).
27. Yuan, L.-P. et al. Protective effects of total flavonoids of *Bidens bipinnata* against carbon tetrachloride-induced liver fibrosis in rats. *J Pharm Pharmacol* 60, 1393–1402 (2008).
28. Tailleux, A. W. K. & Staels, B. Roles of PPARs in NAFLD potential therapeutic targets. *Biochim Biophys Acta* 1821, 809–818 (2012).
29. Martin-Nizard, F. et al. Peroxisome proliferator-activated receptor activators inhibit oxidized low-density lipoprotein-induced endothelin-1 secretion in endothelial cells. *J Cardiovasc Pharmacol* 40, 822–831 (2002).
30. Kang, B. Y., Kleinhenz, J. M., Murphy, T. C. & Hart, C. M. The PPARgamma ligand rosiglitazone attenuates hypoxia-induced endothelin signaling in vitro and in vivo. *Am J Physiol Lung Cell Mol Physiol* 301, L881–891 (2011).
31. Iglarz, M. et al. Peroxisome proliferator-activated receptor-alpha and receptor-gamma activators prevent cardiac fibrosis in mineralocorticoid-dependent hypertension. *Hypertension* 42, 737–743 (2003).
32. Clarke, C. et al. Selenium supplementation attenuates procollagen-1 and interleukin-8 production in fat-loaded human C3A hepatoblastoma cells treated with TGFβ1. *Biochim Biophys Acta* 1800, 611–618 (2010).
33. Liu, T., Wang, X., Karsdal, M. A., Leeming, D. J. & Genovese, F. Molecular serum markers of liver fibrosis. *Biomark Insights* 7, 105–117 (2012).
34. Chang, W.-C. et al. Beneficial effects of soluble dietary Jerusalem artichoke (*Helianthus tuberosus*) in the prevention of the onset of Type 2 diabetes and NAFLD in high fructose-fed rats. *Br J Nutr* 112, 709–717 (2014).
35. Jia, H. et al. Multi-faceted integrated omics analysis revealed Parsley (*Petroselinum crispum*) as a novel dietary intervention in dextran sodium sulphate induced colitic mice. *J Funct Foods* 11, 438–448 (2014).

**Author contributions**
H.J. and H.K. conceived and designed the experiments. H.J. and M.H. performed the experiments and collected the data. H.J., W.A. and K.S. analyzed the data. H.J. wrote and W.A., K.S. and H.K. revised the paper. Y.H. provided samples. All authors reviewed the manuscript.

**Additional information**
Supplementary information accompanies this paper at http://www.nature.com/scientificreports

**Competing financial interests:** The authors declare no competing financial interests.

**How to cite this article:** Jia, H. et al. Eggshell membrane ameliorates hepatic fibrogenesis in human C3A cells and rats through changes in PPARγ-Endothelin 1 signaling. *Sci. Rep.* 4, 7473; DOI:10.1038/srep07473 (2014).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder in order to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/